



ATTORNEY DOCKET NO. 22000.0021

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 13 2001
TECHNICAL CENTER 1600 2900

In re Application of)
Lin et al.) Group Art Unit: 1636
Serial No. 09/516,310) Examiner: Gansheroff, L.
Filed: March 1, 2000)
For: "A NOVEL METHOD FOR IMPORTING)
BIOLOGICALLY ACTIVE MOLECULES)
INTO CELLS")

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

July 11, 2001

Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, issued June 22, 2001
for the above-identified patent application. A copy of the Notice is enclosed herewith.

As required by the Notice, enclosed herewith is an initial computer readable form (CRF)
copy of the Sequence Listing for this patent application and a substitute paper copy of the
Sequence Listing in compliance with 37 C.F.R. §§ 1.821-1.825. Applicants hereby certify that


the information in both the computer readable form and the paper copy of the Sequence Listing is the same and includes no new matter.

Please delete the previous Sequence Listing, consisting of pages 33-39, from the present specification and re-number the remaining pages of the specification accordingly. Please substitute the enclosed Sequence Listing, consisting of pages 1-5, for the previous sequence listing.

No fee is believed due. However, the Commissioner is hereby authorized to charge any fee that may be required, or to credit any overpayment, to Deposit Account No. 14-0629.



Respectfully submitted,


NEEDLE & ROSENBERG, P.C.



Shari J. Corin, Ph.D.
Registration No. 46,243

Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
(404) 688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date shown below.	
 _____ Shari J. Corin	 _____ Date



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RECEIVED

TECH C 16000000

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

EXAMINER

RECEIVED

ART UNIT	PAPER NUMBER
----------	--------------

JUN 25 2001

NEEDLE & ROSENBERG

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

DOCKETED

By JMW Date 6/25/01

Reviewed SJK 6/28/01

Name/Date



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------



EXAMINER

ART UNIT	PAPER
----------	-------

4

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

09/516310

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa Gansheroff whose telephone number is (703) 605-1203. The examiner can normally be reached on Monday - Friday, 9 AM to 5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached at (703) 308-0447. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst Dianiece Jacobs, whose telephone number is (703) 305-3388 or to the receptionist whose telephone number is (703) 308-0196.

JAMES KETTER
PRIMARY EXAMINER